Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Staphylococcal Infections 1Sepsis 1Infections 1Bacteremia 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × telavancin × Clear all
NCT01321879 2019-12-27

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 6 charts

Infections, Staphylococcal Infections, Bacteremia, Sepsis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡